Doctors Address COVID-19 Vaccine Myths During Spanish-Language Webinar prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
FORT COLLINS, Colo., March 16, 2021 /PRNewswire/ Cytocom, Inc., a leading biopharmaceutical company creating next generation immune therapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2, the virus that causes COVID-19. CYTO-205 is designed to modulate immune system function, decrease elevated inflammatory responses associated with viral infection and inhibit viral replication in human lung cells.
The trial, titled, Even as new vaccines are introduced into the market and inoculation programs continue to expand, the need for safe and effective therapies to treat COVID-19 remains undiminished, especially in light of the spread of new, highly contagious variants of the virus, stated Michael Handley, President & CEO of Cytoco
2 Min Read
Published on: 03-16-2021
Children with higher adverse childhood experiences (ACEs), including child maltreatment and household dysfunction, have increased physiological stress responses, potentially leading to elevated health risks later in their life, according to a recent study conducted by researchers at Loma Linda University Health.
Development and Psychopathology on January 28, 2021, explored the link between early life stress exposure in otherwise healthy children ages 5-11. The researchers examined whether ACEs were associated with a chronic stress response that could physiologically wear down a body’s natural defenses over time and put that child at higher risk for health issues over the lifespan.
The WASC Senior College and University Commission has granted Loma Linda University a 10-year academic accreditation, the maximum accreditation award allowed by federal guidelines and the second consecutive such designation for the university.
As eligibility expands, doctors help patients overcome anxiety about vaccine
KABC
Share: The next group of people in California who will be eligible to get the COVID-19 vaccine will be adults with various health conditions such as chronic heart disease and those with disabilities.
But as many doctors are finding out, not everyone in this group is ready to get the vaccine.
This past year has been nerve-racking for heart-failure patient Reggie Allen. I knew that if I got COVID. I would be in serious trouble, he said.
Before the pandemic, the Loma Linda resident needed a device to keep his heart beating and medications to keep it in check.